Tag: nivolumab

Advanced/ Stage 4 Lung Cancer: Approved Immunotherapy in 2nd Line Treatment (Part 1 of 2)

Advanced/ Stage 4 Lung Cancer: Approved Immunotherapy in 2nd Line Treatment (Part 1 of 2)

The above are called immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab) that target and bind to PD-1 or PD-L1, denying PD-1 and PD-L1 linkage. PD-1 is receptors on activated T-cells while PD-1 ligand, PD-L1, is present in normal cells (and also in some tumor cells). Linkage of PD-1 and PD-1 ligand (PD-L1) will cause T-cells to … Continue reading Advanced/ Stage 4 Lung Cancer: Approved Immunotherapy in 2nd Line Treatment (Part 1 of 2)